Aurobindo launches generic Advair Diskus
Analysis based on 7 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The launch opens a significant revenue stream for Aurobindo in the US inhalation market, estimated at $908 million, and intensifies competition with Cipla. It is expected to contribute to Aurobindo's goal of $2 billion US revenue, potentially pressuring GSK's branded Advair sales.
Aurobindo Pharma, through its wholly owned subsidiary Lannett Company Company LLC, has commercially launched a generic version of GSK plc's Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the US market in 100/50 mcg and 250/50 mcg strengths. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in the US, reflecting its focus on expanding its portfolio of complex inhalation products. The drug is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). According to IQVIA, the US market for this product is approximately $908 million. The launch positions Aurobindo against Cipla, which recently received FDA approval for its generic version in all three strengths. Aurobindo's entry into the US inhalation market is part of its strategy to achieve $2 billion annual revenue from the US, following its $250 million acquisition of Lannett Company.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard